Here’s why even bullish analyst Ram Selvaraju of H.C.
Synergy Pharmaceuticals (NASDAQ:SGYP) investors eagerly anticipating news regarding the company’s progress in commercializing its lead drug, Trulance, an FDA-approved treatment for chronic idiopathic …
Oppenheimer’s Christopher Liu thinks the Street is too confident on SGYP ahead of its first earnings show of the year- opting for now to stick to the sidelines.
Though Cantor’s William Tanner keeps SGYP’s capital needs and prospective dilution in mind, he is confident on Trulance’s uptake in the market.
H.C.
Investors snapped up Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares a day after the drug maker released its fourth-quarter results. Surprisingly, SGYP reported 4Q17 Trulance sales …
Two bulls weigh in believing short-term financing pressure on SGYP stock will lessen with the funding reveal.
BTIG’s Tim Chiang says Synergy has a “differentiated product” on its hands compared to the current winning market player: Ironwood/Allergan’s Linzess.
There’s a new FDA-approved IBS-C medication on the scene. Today, the U.
